Get access

Increased Phosphodiesterase Type 5 Levels in a Mouse Model of Type 2 Diabetes Mellitus

Authors

  • Riyad T. Ellati MD,

    1. Department of Urology, University of Virginia Health System, Charlottesville, VA, USA
    Search for more papers by this author
  • Ayotunde O. Dokun MD,

    1. Department of Medicine, University of Virginia Health System, Charlottesville, VA, USA
    2. The Robert M. Berne Cardiovascular Research Center, University of Virginia Health System, Charlottesville, VA, USA
    Search for more papers by this author
  • Parviz K. Kavoussi MD,

    1. Department of Urology, University of Virginia Health System, Charlottesville, VA, USA
    Search for more papers by this author
  • William D. Steers MD,

    1. Department of Urology, University of Virginia Health System, Charlottesville, VA, USA
    Search for more papers by this author
  • Brian H. Annex MD,

    1. Department of Medicine, University of Virginia Health System, Charlottesville, VA, USA
    2. The Robert M. Berne Cardiovascular Research Center, University of Virginia Health System, Charlottesville, VA, USA
    Search for more papers by this author
    • Laboratories contributed equally, J.J.L. and B.H.A. share senior authorship.

  • Jeffrey J. Lysiak PhD

    Corresponding author
    1. Department of Urology, University of Virginia Health System, Charlottesville, VA, USA
    Search for more papers by this author
    • Laboratories contributed equally, J.J.L. and B.H.A. share senior authorship.


Jeffrey J. Lysiak, PhD, Department of Urology, University of Virginia, PO Box 801322, Charlottesville, VA 22908, USA. Tel: 434.924.5007; Fax: 434-924-5007; E-mail: jl6n@virginia.edu

ABSTRACT

Introduction.  Diabetes mellitus (DM) is a major risk factor for developing erectile dysfunction (ED) and men with DM are often less responsive to phosphodiesterase type 5 (PDE5) inhibitors than ED due to other causes.

Aims.  The aim of this study was to explore potential mechanisms whereby PDE5 inhibitors may have reduced efficacy in type 2 DM.

Methods.  At 4 weeks of age, mice were either fed a high-fat diet (HFD) for 22–36 weeks or fed regular chow (control). An additional group of mice in the same genetic background had a genetic form of type 1 DM.

Main Outcome Measures.  Glucose tolerance testing, intracorporal pressures (ICPs), oxidative stress (OS), apoptotic cell death (active caspase-3 and apostain), PDE5, p53, and cyclic guanosine monophosphate (cGMP) levels, and histological examination of inflow arteries were performed in mice fed a HFD and control mice. A group of mice with type 1 DM were studied for PDE5 expression levels.

Results.  All mice fed a HFD had impaired glucose tolerance compared with the age-matched mice fed on standard chow diet (control). HFD fed mice had reduced maximum ICPs following in vivo cavernous nerve electrical stimulation and increased apoptotic cell death, OS, and p53 levels in the corporal tissue. Interestingly, PDE5 levels were increased and cGMP levels were decreased. In contrast, mice with type 1 DM did not have increases in PDE5.

Conclusions.  Taken together, our results suggest that type 2 DM-induced ED is associated with findings that could lead to reduced cGMP and may account for reduced efficacy of PDE5 inhibitors. Ellati RT, Dokun AO, Kavoussi PK, Steers WD, Annex BH, and Lysiak JJ. Increased phosphodiesterase type 5 levels in a mouse model of type 2 diabetes mellitus. J Sex Med **;**:**–**.

Ancillary